Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
49.33
+0.32 (+0.65%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Sanofi-Aventis S.A. ADR
< Previous
1
2
3
Next >
Sanofi (NASDAQ: SNY) Highlighted for Surprising Price Action
March 23, 2023
Via
Investor Brand Network
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
March 23, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
March 18, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
March 13, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Sanofi (NASDAQ: SNY) Set to Acquire Provention Bio (NASDAQ: PRVB) for $2.9 Billion
March 13, 2023
Provention Bio, Inc. (NASDAQ: PRVB) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development and
Via
Spotlight Growth
Analyst Confidence in Eli Lilly Boosted by Product Pipeline
February 22, 2023
Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term.
Via
MarketBeat
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
January 30, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Mergers and Acquisitions in 2023 Off To A Strong Start
January 26, 2023
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.
Via
MarketBeat
Exposures
Product Safety
Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology
December 19, 2022
From
Innate Pharma SA
Via
Business Wire
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
December 09, 2022
Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months.
Via
MarketBeat
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
December 06, 2022
From
Singapore Economic Development Board (EDB)A*STAR
Via
ACN Newswire
NASDAQ:SNY Investor Alert: Investigation over Potential Wrongdoing at Sanofi
September 20, 2022
San Diego, CA -- (SBWIRE) -- 09/20/2022 -- An investigation on behalf of investors in shares of Sanofi (NASDAQ:SNY) was announced over potential breaches of fiduciary duties by certain directors at...
Via
SBWire
MarketBeat: Week in Review 8/15 - 8/19
August 20, 2022
The economic reports continue to signal volatility. You can count on MarketBeat analysts to bring you the stocks and stories that are driving the market.
Via
MarketBeat
Topics
Economy
Workforce
Exposures
Economy
Interest Rates
Layoff
Is Sanofi A Buy, Despite Recent Stumbles?
August 19, 2022
Pharmaceuticals are subject to whiplash trade. That's evident with sharp moves lower in Sanofi, GSK and Teva on news about clinical trials and legal actions.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Millions Suffering From Diabetes May Soon See Relief From Some Of The Pain And Expenses Associated
August 18, 2022
Americans with diabetes have been relying on insulin injections to manage their illness for decades. Those injections can be painful, expensive and inconvenient. The daily invasive testing regimen adds...
Via
TheNewswire.com
Exposures
Product Safety
Sanofi (NASDAQ:SNY) Shareholder Notice: Investigation Concerning Possible Violations of Securities Laws
August 09, 2022
San Diego, CA -- (SBWIRE) -- 08/09/2022 -- Sanofi is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Monkeypox Plays Jockey For Position This Week
August 08, 2022
Via
AB Newswire
Exposures
COVID-19
Product Safety
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm
July 05, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm
July 01, 2022
From
The Schall Law Firm
Via
Business Wire
Pfizer’s CDI Trial Miss Puts Acurx Pharmaceuticals Ibezapolstat In Front-Line Position, Here’s Why Big Pharma May Come Calling ($ACXP)
June 09, 2022
Via
AB Newswire
Exposures
Product Safety
Acurx Pharmaceuticals Is Under The Radar, That’s Excellent News For Investors Wanting Exposure To Billion Dollar CDI Treatment Market ($ACXP)
June 06, 2022
Via
AB Newswire
Exposures
Product Safety
Revolutionary Heart Therapy Offers Hope to Patients and Investors Alike
May 31, 2022
Palm Beach, FL – May 31, 2022 – FinancialNewsMedia.com News Commentary – Diabetes is a chronic health condition that occurs when your body’s blood glucose, also called blood sugar, is too high. Blood...
Via
FinancialNewsMedia
Heart Failure Treatment Offers Hope to Diabetics
May 11, 2022
Palm Beach, FL – May 11, 2022 – FinancialNewsMedia.com News Commentary – Diabetes and heart failure are closely linked. People with type 2 diabetes are two to four times more likely to develop heart...
Via
FinancialNewsMedia
Cognitive Drugs Market Expected Reach Revenues Of $21 Billion in 2027
April 13, 2022
Palm Beach, FL – April 13, 2022 – FinancialNewsMedia.com News Commentary – Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent...
Via
FinancialNewsMedia
Exposures
COVID-19
Acurx Pharmaceuticals Stands As Front-Line CDI Treatment Contender After Pfizer Misses Primary Endpoint In CDI Drug Trial (NASDAQ: ACXP)
March 28, 2022
Via
AB Newswire
Exposures
Product Safety
Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
March 16, 2022
From
Seagen Inc.
Via
Business Wire
Acurx Pharmaceuticals Ibezapolstat Targets Front-Line Opportunity After Pfizer Fails To Reach CDI Trial Primary Endpoint (NASDAQ: ACXP)
March 07, 2022
Via
AB Newswire
Global Multiple Sclerosis Drugs Market Expected to Reach $41.99 Billion in 2028
February 03, 2022
Palm Beach, FL –– February 3, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system. It is characterized by demyelination,...
Via
FinancialNewsMedia
Exposures
COVID-19
Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential
January 24, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 24, 2022 – USA News Group – Within the grand battle against cancer, the use of immunotherapy continues to grow at...
Via
FinancialNewsMedia
Global Alzheimer’s Disease Therapeutics Market Projected To Generate Revenue Of $9.97 Billion By 2028
January 04, 2022
Palm Beach, FL –January 4, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease is a degenerative, progressive ailment that attacks the brain’s nerve cells, resulting in memory loss,...
Via
FinancialNewsMedia
Exposures
COVID-19
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.